

Special Issue

Tendinopathy and Myopathy: From Molecular Basis to Therapy

Message from the Guest Editors

Tendinopathy and myopathy are prevalent musculoskeletal disorders affecting a significant number of individuals. New developments in comprehending tendinopathy and myopathy emphasize an increasing acknowledgment of various biomarkers, microRNAs, lncRNAs, and cellular reactions implicated in their development. Advanced technologies now allow for quantitative assessments of tissue vascularity, echogenicity, and elasticity, providing detailed and precise data that enhance our understanding of various disease processes. Furthermore, upcoming therapeutic approaches encompass stem cells, exosomes, biomaterials, and nanomaterials. This Special Issue titled “Tendinopathy and Myopathy” highlights the progress in the pathogenesis, diagnosis, and treatment of tendinopathies and myopathies. We invite experts worldwide to submit their latest research on this topic. Original articles and reviews are all equally welcomed contributions.

Guest Editors

Dr. Simon Fuk-Tan Tang

1. Department of Physical Medicine and Rehabilitation, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan 333423, Taiwan

2. Department of Physical Medicine and Rehabilitation, Lotung Poh-Ai Hospital, Yilan 265501, Taiwan.

Dr. Carl Pai Chu Chen

Chang Gung Memorial Hospital, Linkou, Taoyuan City, Guishan Township, Taiwan

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/198286

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).